***MATWIN*** *is a French open-innovation platform aiming at selecting and supporting preclinical or early clinical innovations in oncology to optimise their transfer potential for partners (pharma companies, biotechs, investors, etc.). The present form should describe your project from a translational point of view. Your project will first be reviewed and preselected by a multidisciplinary jury before a possible interview by the MATWIN* [*International Board*](https://matwin.fr/en/matwin-international-board/)*. For assistance do not hesitate to contact MATWIN.*

*NEW! This year MATWIN is joining forces with the* [*Paris Saclay Cancer Cluster*](https://www.parissaclaycancercluster.org/en/a-propos) *in order to increase the added value of the support offered!*

**Project**

|  |  |
| --- | --- |
| **Title** |  |
| **Project type** | *Please indicate if it is Therapeutic drug, Medical Device, Diagnostic tool, other* |
| **Acronym** |  |
| **Key words** |  |

**Start-up informations**

|  |  |
| --- | --- |
| **Name** |  |
| **Date of creation** |  |
| **Nb of employees** |  |

**Project Coordinator**

|  |  |  |  |
| --- | --- | --- | --- |
| **Title; Name** |  | | |
| **Position** |  | | |
| **Lab / Organisation** |  | | |
| **Address** |  | | |
| **E-mail** |  | **Phone / Mobile** |  |

**For European project outside France – French established collaborator / potential partners**

|  |  |  |  |
| --- | --- | --- | --- |
| **Collaboration type** |  | | |
| **Title; Name** |  | | |
| **Position** |  | | |
| **Lab / Organisation** |  | | |
| **Address** |  | | |
| **E-mail** |  | **Phone / Mobile** |  |

**ABSTRACT (400 words MAX - NOT CONFIDENTIAL)**

(Summarize your project as NOT confidential, to allow diffusion to peers without jeopardizing proprietary information). **Only the abstract must be considered as NOT confidential.**

C Please, note that your summary must answer the following and indicate your French established collaboration *(for NON French European applicants only)*:

1. Application domain

2. Innovative component / Competitive differentiator

3. Objectives

4. Concept

5. Methodology

6. Expected results

7. Impact

1. **INTELLECTUAL PROPERTY**

**Patent à one table for each patent, filed or granted**

|  |  |
| --- | --- |
| Patent title |  |
| Date of patent filing |  |
| Patent co-owners (institutions) |  |
| National / PCT / WO number |  |
| Freedom To Operate ? Y/N - Patent officer (1 page summary to be joined) |  |
| Potential agreement (license) limiting use of IP? Involved parties & type of agreement? |  |

1. **SCIENTIFIC PROJECT (4-5 PAGES MAX - CONFIDENTIAL)**

* **Context and background (A HALF PAGE MAX):** Describe succinctly the context and the goal to be reached **including the 4-5 more relevant publication references.**
* **Current stage of development (3-4 PAGES MAX):** Describe the project’s development stage relative to the goal to be reached **(bullet points)**, including **the essential / relevant data** justifying your claims regarding the mechanism of action, the proof of concept, benchmarking, etc. with **3-4 figures** of the most relevant and differentiating data.
* **Research & development plan (A HALF PAGE MAX):** List (bullet points) the main steps and GO/No GO to achieve the final goal
* **Conflict of interest or direct competition :** List any person or company that must be rejected as reviewer

# UNDERTAKING

## Project Leader (and TTO representative if applicable)

*The parties, undersigned confirm that they (i) completed all sections and that all information given in this form is complete and true, (ii) obtained the agreement of collaborators and institutional contacts for their participation (iii)* ***fully agree with the Charter on Rights and Duties of MATWIN applicants (hereafter*:**[*https://matwin.fr/en/matwins-call-for-application/*](https://matwin.fr/en/matwins-call-for-application/) *The parties authorise MATWIN to share this application form for review, given that every reviewer has signed a NDA with MATWIN and that any person/company with potential conflict of interest (listed above) has been refuted.*

|  |
| --- |
| **Name of the leader applicant :** |
| **Date and Signature** |

File to be sent to: [contact@matwin.fr](mailto:contact@matwin.fr) before 2024 January 31st